Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 482 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2020  |  Volume : 31  |  Issue : 5  |  Page : 1014-1024
The Comparison Spondin 2 Levels in Primary Glomerular Diseases

1 Department of Nephrology, Health Science University Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
2 Department of Nephrology, Uludag University Faculty of Medicine, Bursa, Turkey
3 Department of Biochemistry, Health Science University Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
4 Department of Nephrology, Bursa City Hospital, Bursa, Turkey
5 Department of Internal Medicine, Gürsu Cüneyt Yildiz State Hospital, Bursa, Turkey
6 Department of Nephrology, Hitit University Erol Olçok Training and Research Hospital, Çorum, Turkey

Correspondence Address:
Selin Akturk Esen
Department of Internal Medicine, Gürsu Cüneyt Yildiz State Hospital, Bursa
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1319-2442.301166

Rights and Permissions

Spondin 2 (SPON2) plays an important role in multiple processes and is a member of the Spondin 2/F-spondin family of extracellular matrix proteins. We investigated serum SPON2 levels and its correlation with renal functions and urine protein excretion in different glomerular diseases. The cohort included 97 consecutive adults with persistant proteinuria (>300 mg/day) with the diagnosis of focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MN), IgA nephropathy (IgAN), membranoproliferative glomerulonephritis (MPGN), and AA amyloidosis and the control groups with 15 polycystic kidney disease (PKD) and 32 healthy people. Serum SPON2 levels in MN (64.6 ng/mL), FSGS (47.8 ng/mL), IgAN (52.6 ng/mL), MPGN (54.6 ng/mL), and AA amyloidosis (60.7 ng/mL) groups were higher than those of the control (26.4 ng/mL) and nonglomerular disease groups (PKD) (15.3 ng/mL). Only serum SPON2 levels were correlated with serum uric acid and triglyceride levels in patients with glomerular disease. This is the first study to show that serum SPON2 levels are similar in different glomerular diseases and that there is no correlation between SPON2 and proteinuria grade.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded224    
    Comments [Add]    

Recommend this journal